1. Real-world impact of brain metastases on healthcare utilization and costs in patients with non-small cell lung cancer treated with EGFR-TKIs in the US
- Author
-
Hairong Huo, Stella Min, Amanda M Kong, Deepa S. Subramaniam, Melissa Pavilack, Rahul Shenolikar, Christina Chebili-Larson, Meghan Moynihan, and Elizabeth Hoit Marchlewicz
- Subjects
Oncology ,medicine.medical_specialty ,Lung Neoplasms ,Antineoplastic Agents ,Insurance Claim Review ,03 medical and health sciences ,Egfr tki ,Sex Factors ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,In patient ,Epidermal growth factor receptor ,Lung cancer ,Protein Kinase Inhibitors ,Aged ,biology ,Brain Neoplasms ,business.industry ,030503 health policy & services ,Health Policy ,Age Factors ,Middle Aged ,medicine.disease ,respiratory tract diseases ,ErbB Receptors ,Models, Economic ,Socioeconomic Factors ,Healthcare utilization ,030220 oncology & carcinogenesis ,biology.protein ,Health Resources ,Non small cell ,Health Expenditures ,0305 other medical science ,business - Abstract
Non-small cell lung cancer (NSCLC) with brain metastases (BM) is difficult to treat and associated with poor survival. This study assessed the impact of BM on healthcare-related utilization and costs (HRUC) among patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).Adults newly-diagnosed with metastatic NSCLC, initiating first-/second-generation EGFR-TKI treatment, with BM or no BM (NBM), were identified retrospectively from IBM MarketScan healthcare claims databases (2013-2017). HRUC were measured during the variable-length follow-up period. Generalized linear models assessed the impact of BM on total healthcare costs, standardized to 2017 US$.Overall, 222 BM and 280 NBM patients were included, with a mean duration of follow-up of 14 months. Adjusted NSCLC-related and all-cause costs over average follow-up were 1.2 times higher among BM patients (Δ$5,640 and Δ$6,366, respectively;NSCLC-related HRUC, especially those attributable to radiation treatment, were higher among patients with BM. Future research should compare the potential for CNS-active EGFR-TKIs vs first-/second-generation EGFR-TKIs combined with radiotherapy to reduce HRUC.
- Published
- 2021
- Full Text
- View/download PDF